戴德梁行-2021上海生物医药产业生态报告_16页_27mb

报告摘要

Summary of Shanghai's Biopharmaceutical Industry Environment Report (2021)

Core Content

This report provides an overview of the global and Chinese biopharmaceutical markets, with a specific focus on Shanghai's position within the industry. It includes a SWOT analysis and market outlook for the city's biopharmaceutical sector, highlighting its strengths, weaknesses, opportunities, and threats.

Main Points

Global Biopharmaceutical Market Overview

The global pharmaceutical and medical device market has expanded significantly, driven by increased healthcare awareness, rising incomes, a larger pool of healthcare professionals, and greater integration with technology.
The market is expected to continue growing, with a strong emphasis on innovation and R&D.

China Biopharmaceutical Market Overview

The Chinese biopharmaceutical industry has grown rapidly since the 1980s, with foreign companies playing a key role in its early development.
In recent years, the approval process for drugs has become more efficient, encouraging overseas Chinese talent to return and contribute to the industry.
The market size of China's biopharmaceutical industry is estimated to be around RMB3.57 trillion in 2021, with projections to exceed RMB4 trillion in 2022.
China is targeting to become one of the world's most mature and important biopharmaceutical markets, investing heavily in R&D and innovation.

Shanghai Biopharmaceutical Market Overview

Since 2009, Shanghai has implemented development plans to support the biopharmaceutical industry, leading to the establishment of a complete industrial chain from R&D to sales.
By 2020, the industry size reached RMB600 billion, a six-fold increase from 2008.
Shanghai is home to a high concentration of both global and national biopharmaceutical enterprises.
The city has issued several supportive policies to promote the industry, including financial incentives for R&D and clinical trials.
Shanghai is the top city in China for listed biopharmaceutical companies, with the highest R&D investment in 2020 at RMB8.7 billion.

Key Policies and Financial Support

Financial Support for R&D

Shanghai: Offers up to 40% of R&D investment as financial support, with caps of RMB5 million, RMB10 million, and RMB30 million for different product types. Companies can receive up to RMB100 million in annual support.
Suzhou: Provides one-time grants of RMB1 million, RMB1.5 million, and RMB2.5 million for Phase I, II, and III clinical trials, respectively. Annual support can reach up to US$30 million.
Shenzhen: Offers up to 40% of R&D investment support, with caps of RMB8 million for clinical approval and RMB30 million for Phase III trials. Annual support is capped at RMB100 million.
Chengdu: Provides up to RMB3 million for Phase III trials and RMB10 million for individual enterprises. Support is also available for medical devices with independent intellectual property.

Support for Overseas Markets

Shanghai: Grants up to 30% of R&D investment for products registered with international institutions such as the FDA, EMA, CE, PMDA, or WHO, with a one-time cap of RMB10 million.
Suzhou: Offers RMB1 million in support for products approved by the FDA, EMA, PMDA, etc., with a cap of RMB5 million per enterprise.
Shenzhen: Provides up to RMB10 million in annual support for products certified by international authorities.
Chengdu: Offers up to RMB2 million in subsidies for certified production lines.

SWOT Analysis

Strengths

High concentration of leading biopharmaceutical and innovative enterprises
Strong clinical research capability, with 6 National Clinical Medical Research Centers and 1 National Clinical Medical Center.
Complete industrial chain, including global and national enterprises.
High concentration of foreign biopharmaceutical enterprises
Better financing environment, especially for the biopharmaceutical sector.

Weaknesses

Lack of production bases for active pharmaceutical ingredients (APIs)
Higher industrial land prices compared to other Chinese cities.

Opportunities

Policy support: Shanghai is one of the six cities selected for a pilot program to deepen reform policies, enhancing its appeal for foreign investment.
Control of the COVID-19 epidemic: Shanghai's thorough prevention measures have allowed for normal business operations, attracting further investment.
Technological opportunities: Leveraging China's advancements in 5G, 6G, and AI, Shanghai is expected to drive the development of high-end medical devices and software.

Threats

Competition from other cities: Other Chinese cities are investing heavily in genetic engineering, AI, and other emerging biopharmaceutical fields, posing a challenge to Shanghai's continued leadership.

Market Outlook

With political and capital support, Shanghai aims to further promote R&D in all biopharmaceutical sectors, including Zhangjiang.
The city plans to establish a strong "Made in Shanghai" brand, focusing on innovative medicines and medical devices.
Shanghai is expected to solidify its position as a world-class biopharmaceutical hub.

Key Figures and Data

Figure 1: Global Pharmaceutical Market Revenue (2001-2020)
Figure 2: Number of out-licensed domestic drugs in China (2017-2020)
Figure 3: Health Expenditure Per Capita in China (2010/2020)
Figure 4: Scale of Shanghai's biopharmaceutical industry (2008-2020)
Figure 5: World's top 10 CXO companies (70% have operations in Shanghai)
Figure 6: Comparison of financial support for crucial biopharmaceutical product R&D in major cities in China
Figure 7: Net inflow ranking for Chinese talent returning from overseas (Shanghai ranks second)
Figure 8: Financing events in the biopharmaceutical sector in China (2020)
Figure 9: Location of major biopharmaceutical companies in Shanghai (2021)

Contact Information

Business Contacts

Kelvin Li
Managing Director, East China
Email: kelvin.qw.li@cushwake.com
Jonathan Wei
Managing Director, Head of Project and Occupier Services China
Email: jonathan.cy.wei@cushwake.com
Tony Su
Managing Director, Head of Industrial Property Services China
Email: tony.zy.su@cushwake.com

Research Contacts

James Shepherd
Managing Director, Head of Business Development Services, Greater China
Email: james.shepherd@cushwake.com
Shaun Brodie
Senior Director, East China & Greater China Content
Email: shaun.fv.brodie@cushwake.com
Sabrina Wei
Senior Associate Director, Head of Research, North China
Email: sabrina.d.wei@cushwake.com
XiaoDuan Zhang
Senior Director, Head of Business Development Services, South China
Email: xiaoduan.zhang@cushwake.com
Keith Chan
Director, Head of Research, Hong Kong
Email: keith.chan@cushwake.com
Wendy Hsueh
Director, Head of Research, Taiwan
Email: wendy.hj.hsueh@cushwake.com
Larry Sang
Assistant Manager, East China Research
Email: larry.sang@cushwake.com

About Cushman & Wakefield

A leading global real estate services firm with a presence in 60 countries and 400 offices.
Has 50,000 employees and won four of the top awards in the Euromoney Survey in 2017, 2018, and 2020.
Revenue in 2020 was $7.8 billion across core services.
Website: www.cushmanwakefield.com

Disclaimer

This report is for informational purposes only and not a complete description of the markets.
Information is sourced from public data and not verified.
No warranty or guarantee is made regarding the accuracy or completeness of the information.
Cushman & Wakefield shall not be liable for any decisions made based on this report.

展开完整摘要